Clinical trial
A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)
NCT02689921 is registered in ClinicalTrials.gov with Midwestern Regional Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)
- Lead sponsor
- Midwestern Regional Medical Center
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 30, 2016
- Completion date
- December 31, 2018
- Enrollment
- 7 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.